T. Bryant

The accused, Kadah Dematas, was charged with four counts related to offences committed during his arrest by police officers, including assault with a weapon and assault causing bodily harm.

The trial focused on the accused's knowledge that the complainants were police officers, whether his actions were a reflex, and if he acted in self-defence.

The court found the accused's testimony not credible, concluding that he intentionally assaulted both officers, knowing they were police, and was not acting in self-defence or reflexively.

Dematas was found guilty of assault with a weapon and assault causing bodily harm against Detective Constable Subramaniam, and assault causing bodily harm against Detective Constable Miller.

He was found not guilty of assault with a weapon against Detective Constable Miller.

The matter was adjourned for sentencing.

The accused was charged with assault and forcible confinement arising from an incident on August 20, 2016, during which he allegedly punched the complainant in the eye and confined her in his home against her will.

The Crown called the complainant as its primary witness, while the accused testified in his own defence and called two character witnesses.

The court found the complainant to be a credible witness and accepted her evidence that the accused intentionally struck her in the eye, resulting in a conviction for assault.

However, the court was left in reasonable doubt regarding the forcible confinement allegation and dismissed that charge.

The decision turned on credibility assessments, with the court finding the accused's testimony to be evasive and self-serving, while the complainant's account was straightforward and corroborated by the severity of her injuries.

The defendants were charged with multiple offences under the Food and Drugs Act relating to the sale, importation, and advertising of 1-(Phenylmethyl) Piperazine (BZP), a synthetic substance sold under brand names including Freq, Peaq, Rush, Rush 2, Spun, and Flow.

The Crown alleged the defendants sold these products without proper drug identification numbers (DINs), without filing new drug submissions, and without proper labeling.

The defendants argued that Health Canada had not determined BZP was a drug during the relevant timeframe and that the charges were duplicative.

The court found that the Crown proved the actus reus of the offences beyond a reasonable doubt, that Adam Wookey was the controlling mind of Purepillz Corporation, and that Health Canada had clearly identified BZP as a drug subject to regulation from at least April 2008 onward.

The court convicted on counts 1-6, 8-13, 29, and 33, and stayed counts 15-20 and 22-27 as duplicative under the Kienapple principle.

All charges against Pure Principles Inc. were dismissed due to insufficient evidence.